Abstract
Prevalence of arterial hypertension is up to 30–40% in epidemiological studies, it increases with aging and affects the cardiovascular risk. Essential form of hypertension is the most frequent; however, 5–10% of patients are affected by a specific and potentially reversible cause of increased blood pressure levels, called secondary hypertension. In general, all patients with young onset-age (< 40–50 years) or resistant hypertension should be screened for secondary forms. Among them, primary aldosteronism, Cushing’s Syndrome and pheochromocytoma are the most common cause of endocrine hypertension associated with an autonomous secretion of adrenal hormones, often secondary to a tumor (either mono- or bi-lateral, or not always in the adrenals). Their diagnosis could be challenging, especially in patients with hypertension as the first (and/or isolated) clinical manifestation. Moreover, they are all rare form of hypertension, therefore a correct screening with a sensitive test is mandatory, to refer quickly the patients to an Endocrine Unit. In this short review we pinpoint our attention to these adrenal-related secondary form of hypertension, describing in a concise way their first-line screening procedures.
Similar content being viewed by others
References
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219. https://doi.org/10.1093/eurheartj/eht151.
Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245–54. https://doi.org/10.1093/eurheartj/eht534.
Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–26. https://doi.org/10.1161/CIRCULATIONAHA.108.189141.
El Ghorayeb N, Bourdeau I, Lacroix A. Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism. Front Endocrinol (Lausanne). 2016;7(June):1–10. https://doi.org/10.3389/fendo.2016.00072.
Ceccato F, Scaroni C, Boscaro M. The adrenal glands. In: Belfiore A, LeRoith D, editors. Principles of endocrinology and hormone action, Chap 15. Switzerland: Springer; 2016. p. 387–421. https://doi.org/10.1007/978-3-319-27318-1_16-1.
Monticone S, D’Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50. https://doi.org/10.1016/S2213-8587(17)30319-4.
Cicala MV, Mantero F. Hypertension in Cushing’s Syndrome: from pathogenesis to treatment. Neuroendocrinology. 2010;92(1):44–9. https://doi.org/10.1159/000314315.
Isidori A, Graziadio C, Paragliola R, et al. The hypertension of Cushingʼs syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens. 2015;33(1):44–60. https://doi.org/10.1097/HJH.0000000000000415.
Eisenhofer G. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56(3):331–49. https://doi.org/10.1124/pr.56.3.1.
Lenders JWM, Eisenhofer G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab. 2017;32(2):152. https://doi.org/10.3803/EnM.2017.32.2.152.
Funder J, Carey R, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916. https://doi.org/10.1210/jc.2015-4061.
Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40. https://doi.org/10.1210/jc.2008-0125.
Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42. https://doi.org/10.1210/jc.2014-1498.
Sabbadin C, Fallo F. Hyperaldosteronism: screening and diagnostic tests. High Blood Press Cardiovasc Prev. 2016;23(2):69–72. https://doi.org/10.1007/s40292-016-0136-5.
Williams TA, Reincke M. MANAGEMENT OF ENDOCRINE DISEASE: diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol. 2018;179(1):R19–29. https://doi.org/10.1530/EJE-17-0990.
Cicala MV, Mantero F. Primary aldosteronism: what consensus for the diagnosis. Best Pract Res Clin Endocrinol Metab. 2010;24(6):915–21. https://doi.org/10.1016/j.beem.2010.10.007.
Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91(2):454–9. https://doi.org/10.1210/jc.2005-1733.
Fischer E, Adolf C, Pallauf A, et al. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrinol Metab. 2013;98(6):2513–20. https://doi.org/10.1210/jc.2012-3934.
Hanslik G, Wallaschofski H, Dietz A, et al. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn’s Registry. Eur J Endocrinol. 2015;173(5):665–75. https://doi.org/10.1530/EJE-15-0450.
Beuschlein F, Mulatero P, Asbach E, et al. The SPARTACUS Trial: controversies and unresolved issues. Horm Metab Res. 2017;49(12):936–42. https://doi.org/10.1055/s-0043-120524.
Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med. 1987;147(7):1289–93. http://www.ncbi.nlm.nih.gov/pubmed/3606286.
Anderson GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12(5):609–15. http://www.ncbi.nlm.nih.gov/pubmed/7930562.
Ariton M, Juan CS, AvRuskin TW. Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocr Pract. 2018;6(3):249–52. https://doi.org/10.4158/ep.6.3.249.
Wyszyńska T, Cichocka E, Wieteska-Klimczak A, Jobs K, Januszewicz P. A single pediatric center experience with 1025 children with hypertension. Acta Paediatr. 1992;81(3):244–46. http://www.ncbi.nlm.nih.gov/pubmed/1511199.
Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637–44. https://doi.org/10.1210/jcem.85.2.6372.
Lafont M, Fagour C, Haissaguerre M, et al. Per-operative hemodynamic instability in normotensive patients with incidentally discovered pheochromocytomas. J Clin Endocrinol Metab. 2015;100(2):417–21. https://doi.org/10.1210/jc.2014-2998.
Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G34. https://doi.org/10.1530/EJE-16-0467.
Shimon I. Screening for Cushing’s syndrome: is it worthwhile? Pituitary. 2015;18(2):201–5. https://doi.org/10.1007/s11102-015-0634-9.
Ceccato F, Boscaro M. Cushing’s syndrome: screening and diagnosis. High Blood Press Cardiovasc Prev. 2016;23(3):209–15. https://doi.org/10.1007/s40292-016-0153-4.
Boscaro M, Arnaldi G. Approach to the patient with possible Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(9):3121–31. https://doi.org/10.1210/jc.2009-0612.
Dekkers OM, Horváth-Puhó E, Jørgensen JOL, et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab. 2013;98(6):2277–84. https://doi.org/10.1210/jc.2012-3582.
Hirsch D, Shimon I, Manisterski Y, et al. Cushing’s syndrome: comparison between Cushing’s disease and adrenal Cushing’s. Endocrine. 2018. https://doi.org/10.1007/s12020-018-1709-y.
Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27(3):193–202. https://doi.org/10.1291/hypres.27.193.
Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev. 1998;19(5):647–72. https://doi.org/10.1210/edrv.19.5.0346.
Tirabassi G, Boscaro M, Arnaldi G. Harmful effects of functional hypercortisolism: a working hypothesis. Endocrine. 2014;46(3):370–86. https://doi.org/10.1007/s12020-013-0112-y.
Ceccato F, Antonelli G, Barbot M, et al. The diagnostic performance of urinary free cortisol is better than the cortisol: cortisone ratio in detecting de novo Cushing’s syndrome: the use of a LC–MS/MS method in routine clinical practice. Eur J Endocrinol. 2014;171(1):1–7. https://doi.org/10.1530/eje-14-0061.
Ceccato F, Barbot M, Zilio M, et al. Screening tests for Cushing’s syndrome: urinary free cortisol role measured by LC–MS/MS. J Clin Endocrinol Metab. 2015;100(10):3856–61. https://doi.org/10.1210/jc.2015-2507.
Ceccato F, Antonelli G, Frigo AC, et al. First-line screening tests for Cushing’s syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC–MS/MS. J Endocrinol Investig. 2017;40(7):753–60. https://doi.org/10.1007/s40618-017-0644-8.
Raff H. Cushing’s syndrome: diagnosis and surveillance using salivary cortisol. Pituitary. 2012;15(1):64–70. https://doi.org/10.1007/s11102-011-0333-0.
Ceccato F, Barbot M, Zilio M, et al. Performance of salivary cortisol in the diagnosis of Cushing’s syndrome, adrenal incidentaloma, and adrenal insufficiency. Eur J Endocrinol. 2013;169(1):31–6. https://doi.org/10.1530/eje-13-0159.
Deutschbein T, Broecker-Preuss M, Flitsch J, et al. Salivary cortisol as a diagnostic tool for Cushing’s syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. Eur J Endocrinol. 2012;166(4):613. https://doi.org/10.1530/EJE-11-0945.
Ceccato F, Marcelli G, Martino M, et al. The diagnostic accuracy of increased late night salivary cortisol for Cushing’s syndrome: a real-life prospective study. J Endocrinol Investig. 2018. https://doi.org/10.1007/s40618-018-0921-1.
Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cavagnini F. Specificity of first-line tests for the diagnosis of Cushing’s syndrome: assessment in a large series. J Clin Endocrinol Metab. 2007;92(11):4123–9. https://doi.org/10.1210/jc.2007-0596.
Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008;93(5):1553–62. https://doi.org/10.1210/jc.2008-0139.
Valassi E, Swearingen B, Lee H, et al. Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(12):4851–9. https://doi.org/10.1210/jc.2009-1500.
Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–31. https://doi.org/10.1210/jc.2015-1818.
Ceccato F, Barbot M, Zilio M, Albiger N, Mantero F, Scaroni C. Therapeutic strategies for Cushing’s syndrome: an update. Expert Opin Orphan Drugs. 2015;3(1):45–56. https://doi.org/10.1517/21678707.2015.991714.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflicts of interest that might be perceived as influencing the impartiality of the reported research.
Funding
This study did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Research involving human participants and patient consent
Informed consent to describe patients’ history has been obtained.
Additional information
This article is part of the topical collection on Secondary Hypertension.
Rights and permissions
About this article
Cite this article
Grasso, M., Boscaro, M., Scaroni, C. et al. Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor. High Blood Press Cardiovasc Prev 25, 345–354 (2018). https://doi.org/10.1007/s40292-018-0288-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40292-018-0288-6